Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/EBIT ratio high or low?
The EV/EBIT ratio of 109.12x is 17% below its estimated 1-year average of 130.84x, near the low end of its estimated 1-year range (109.12x–143.72x).
As of 2026-10-06T11:05:27.037Z.
Calculation as of: 2026-10-06T11:05:27.037Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3b719543d2ad964e34cebd38a4954272106044749b474b483c00e469aab85807
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
109.12x
EV/EBIT RATIO AVG TTM
N/A
EV/EBIT RATIO AVG 3Y
N/A
EV/EBIT RATIO AVG 5Y
N/A
EV/EBIT RATIO AVG 10Y
N/A
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
22.54x
median of 120 covered companies
CURRENT VS SECTOR MEDIAN
+384.22%
vs the sector median at left
Market Cap
$14.97B
EV/EBIT Ratio
36.06x
TTM Avg
49.93x
3Y Avg
39.70x
5Y Avg
34.17x
Market Cap
$13.19B
EV/EBIT Ratio
2043.65x
TTM Avg
598.71x
3Y Avg
197.00x
5Y Avg
123.59x
Market Cap
$15.24B
EV/EBIT Ratio
9.69x
TTM Avg
15.83x
3Y Avg
16.38x
5Y Avg
16.38x
Market Cap
$12.89B
EV/EBIT Ratio
18.45x
TTM Avg
15.92x
3Y Avg
20.76x
5Y Avg
30.03x
Market Cap
$12.52B
EV/EBIT Ratio
N/A
TTM Avg
440.49x
3Y Avg
243.05x
5Y Avg
134.16x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ascendis Pharma A/S (ASND) | $14.16B | 109.12x | N/A | N/A | N/A |
| Tempus AI, Inc. (TEM)vs › | $14.64B | N/A | N/A | N/A | N/A |
| Exelixis, Inc. (EXEL)vs › | $14.79B | 15.11x | 14.69x | 34.35x | 31.44x |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.97B | 36.06x | 49.93x | 39.70x | 34.17x |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 2043.65x | 598.71x | 197.00x | 123.59x |
| Solventum Corporation (SOLV)vs › | $15.24B | 9.69x | 15.83x | 16.38x | 16.38x |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | N/A | N/A | N/A | N/A |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 18.45x | 15.92x | 20.76x | 30.03x |
| Baxter International Inc. (BAX)vs › | $12.52B | N/A | 440.49x | 243.05x | 134.16x |
| Penumbra, Inc. (PEN)vs › | $12.49B | 66.71x | 68.46x | 853.99x | 925.32x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-10-05 | 120.36x |
| 2026-10-02 | 120.27x |
| 2026-10-01 | 119.97x |
| 2026-09-30 | 120.25x |
| 2026-09-29 | 120.38x |
| 2026-09-28 | 121.45x |
| 2026-09-25 | 119.04x |
| 2026-09-24 | 121.80x |
| 2026-09-23 | 117.70x |
| 2026-09-22 | 125.53x |
| 2026-09-21 | 125.54x |
| 2026-09-18 | 125.07x |
| 2026-09-17 | 126.33x |
| 2026-09-16 | 131.02x |
| 2026-09-15 | 126.72x |
| 2026-09-14 | 140.36x |
| 2026-09-11 | 139.60x |
| 2026-09-10 | 138.36x |
| 2026-09-09 | 138.13x |
| 2026-09-08 | 143.16x |
| 2026-09-04 | 143.42x |
| 2026-09-03 | 143.72x |
| 2026-09-02 | 141.65x |
| 2026-09-01 | 137.83x |
| 2026-08-31 | 139.34x |
| 2026-08-28 | 131.14x |
| 2026-08-27 | 131.92x |
| 2026-08-26 | 132.40x |
| 2026-08-25 | 133.89x |
| 2026-08-24 | 133.33x |
| 2026-08-21 | 134.05x |
| 2026-08-20 | 134.88x |
| 2026-08-19 | 137.49x |
| 2026-08-18 | 131.65x |
| 2026-08-17 | 130.86x |
| 2026-08-14 | 131.46x |
